Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex.

Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H.

Circ Res. 2013 Mar 1;112(5):771-80. doi: 10.1161/CIRCRESAHA.111.300049. Epub 2013 Jan 10. Erratum in: Circ Res. 2013 Apr 26;112(9):e98.

PMID:
23307819
2.

Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.

Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Horiguchi CS, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H.

Diabetes. 2012 Nov;61(11):2823-32. doi: 10.2337/db12-0232. Epub 2012 Jul 26.

3.

Platelet-rich plasma stimulates osteoblastic differentiation in the presence of BMPs.

Tomoyasu A, Higashio K, Kanomata K, Goto M, Kodaira K, Serizawa H, Suda T, Nakamura A, Nojima J, Fukuda T, Katagiri T.

Biochem Biophys Res Commun. 2007 Sep 14;361(1):62-7. Epub 2007 Jul 5.

PMID:
17632078
4.

Purification and identification of a BMP-like factor from bovine serum.

Kodaira K, Imada M, Goto M, Tomoyasu A, Fukuda T, Kamijo R, Suda T, Higashio K, Katagiri T.

Biochem Biophys Res Commun. 2006 Jul 7;345(3):1224-31. Epub 2006 May 15.

PMID:
16716261
5.

[Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)].

Tomoyasu A, Higashio K.

Nihon Rinsho. 2004 Feb;62 Suppl 2:560-5. Review. Japanese. No abstract available.

PMID:
15035190
6.

Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T.

J Biol Chem. 2003 Jun 27;278(26):23971-7. Epub 2003 Apr 15.

7.

Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype.

Yamashita T, Okada S, Higashio K, Nabeshima Y, Noda M.

Endocrinology. 2002 Dec;143(12):4711-7.

PMID:
12446599
8.

Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis.

Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K.

J Bone Miner Metab. 2002;20(6):337-44.

PMID:
12434161
9.

[Merger of bone biology and immunology].

Suda T, Shima N, Higashio K.

Tanpakushitsu Kakusan Koso. 2002 Oct;47(13):1837-43. Review. Japanese. No abstract available.

PMID:
12385106
10.
12.

Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy.

Yano K, Shibata O, Mizuno A, Kobayashi F, Higashio K, Morinaga T, Tsuda E.

Biochem Biophys Res Commun. 2001 Oct 19;288(1):217-24.

PMID:
11594776
13.

Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.

Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.

J Bone Miner Res. 2001 Oct;16(10):1787-94.

14.

Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.

Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, Higashio K, Quinn JM, Gillespie MT, Martin TJ, Suda T, Takahashi N.

Endocrinology. 2001 Aug;142(8):3656-62.

PMID:
11459815
15.

Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.

Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M.

J Biol Chem. 2001 Apr 20;276(16):13065-71. Epub 2001 Jan 22.

16.

Hepatocyte growth factor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage in vitro.

Oh SH, Miyazaki M, Kouchi H, Inoue Y, Sakaguchi M, Tsuji T, Shima N, Higashio K, Namba M.

Biochem Biophys Res Commun. 2000 Dec 20;279(2):500-4.

PMID:
11118315
17.

A deleted form of human hepatocyte growth factor stimulates hepatic lipogenesis and lipoprotein synthesis in rats.

Shiota A, Yamashita Y, Fujise N, Masunaga H, Yasuda H, Higashio K.

Pharmacol Res. 2000 Nov;42(5):443-52.

PMID:
11023706
18.

Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.

Endocrinology. 2000 Sep;141(9):3478-84.

PMID:
10965921
19.

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T.

J Exp Med. 2000 Jan 17;191(2):275-86.

20.

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.

Bone. 1999 Nov;25(5):517-23.

PMID:
10574571
21.

Deleted form of hepatocyte growth factor ameliorates the mortality rate of severe thermal injury in rats.

Arisawa H, Yamashita Y, Ogawa H, Masunaga H, Higashio K.

Surgery. 1999 Nov;126(5):925-32.

PMID:
10568193
22.

Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells.

Nakagawa N, Yasuda H, Yano K, Mochizuki Si, Kobayashi N, Fujimoto H, Shima N, Morinaga T, Chikazu D, Kawaguchi H, Higashio K.

Biochem Biophys Res Commun. 1999 Nov;265(1):158-63.

PMID:
10548507
23.

Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor.

Nakagawa N, Yasuda H, Yano K, Mochizuki Si, Kobayashi N, Fujimoto H, Yamaguchi K, Shima N, Morinaga T, Higashio K.

Biochem Biophys Res Commun. 1999 Nov;265(1):45-50.

PMID:
10548488
24.

A novel molecular mechanism modulating osteoclast differentiation and function.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K.

Bone. 1999 Jul;25(1):109-13.

PMID:
10423033
25.

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.

Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y.

J Bone Miner Res. 1999 Apr;14(4):518-27.

26.

Cloning and characterization of the gene encoding mouse osteoclast differentiation factor.

Kodaira K, Kodaira K, Mizuno A, Yasuda H, Shima N, Murakami A, Ueda M, Higashio K.

Gene. 1999 Apr 1;230(1):121-7.

PMID:
10196481
27.

A mutant of deleted variant of hepatocyte growth factor (dHGF) with alanine substitution in the N-terminal basic region has higher activity in vivo.

Kinosaki M, Yamaguchi K, Yamashita Y, Uematsu Y, Aihara H, Masunaga H, Morinaga T, Higashio K.

Biochem Biophys Res Commun. 1999 Jan 19;254(2):363-7.

PMID:
9918843
28.

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K.

Biochem Biophys Res Commun. 1998 Dec 18;253(2):395-400.

PMID:
9878548
29.

Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects.

Uematsu Y, Fujise N, Kohsaka K, Masunaga H, Higashio K.

J Pharm Sci. 1999 Jan;88(1):131-5.

PMID:
9874714
30.

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.

Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N.

Bone. 1998 Dec;23(6):495-8.

PMID:
9855457
31.

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, Miyata T, Kumegawa M.

Biochem Biophys Res Commun. 1998 Oct 29;251(3):796-801.

PMID:
9790989
33.

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.

Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y.

J Biol Chem. 1998 Oct 16;273(42):27091-6.

34.

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N.

Biochem Biophys Res Commun. 1998 Sep 18;250(2):229-34.

PMID:
9753612
36.

Hepatocyte apoptosis and hepatic expression of transforming growth factor-beta1 mRNA during involution of hyperplastic rat liver induced by hepatocyte growth factor.

Nagoshi S, Yasuda H, Suda J, Yamanobe F, Ohno A, Higashio K, Fujiwara K.

J Gastroenterol Hepatol. 1998 Aug;13(8):786-93.

PMID:
9736171
37.

Possible involvement of p21/waf1 in the growth inhibition of HepG2 cells induced by hepatocyte growth factor.

Shima N, Stolz DB, Miyazaki M, Gohda E, Higashio K, Michalopoulos GK.

J Cell Physiol. 1998 Oct;177(1):130-6.

PMID:
9731753
38.

Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.

Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki S, Higashio K, Akatsu T, Motoyoshi K, Nagata N.

Endocrinology. 1998 Sep;139(9):4012-5.

PMID:
9724059
39.

Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis.

Mizuno A, Murakami A, Nakagawa N, Yasuda H, Tsuda E, Morinaga T, Higashio K.

Gene. 1998 Jul 30;215(2):339-43.

PMID:
9714833
40.

Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor.

Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K.

Eur J Biochem. 1998 Jun 15;254(3):685-91.

41.

[Osteoclastogenesis inhibitory factor (OCIF)/OPG].

Tsuda E, Higashio K.

Nihon Rinsho. 1998 Jun;56(6):1435-9. Review. Japanese.

PMID:
9648461
42.

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H.

Biochem Biophys Res Commun. 1998 Jun 29;247(3):610-5.

PMID:
9647741
43.

Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.

Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K.

Biochem Biophys Res Commun. 1998 May 19;246(2):337-41.

PMID:
9610359
44.

Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF).

Kinosaki M, Yamaguchi K, Murakami A, Ueda M, Morinaga T, Higashio K.

Biochim Biophys Acta. 1998 Apr 23;1384(1):93-102.

PMID:
9602078
45.

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T.

Biochem Biophys Res Commun. 1998 May 8;246(1):199-204.

PMID:
9600092
46.

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602.

47.

Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.

Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K.

Biochem Biophys Res Commun. 1998 Apr 17;245(2):382-7.

PMID:
9571159
48.

Effects of the deleted form of hepatocyte growth factor on serum hyaluronate levels in rats with liver cirrhosis.

Yamashita Y, Shiota A, Fujise N, Ogawa H, Masunaga H, Yasuda H, Higashio K.

J Vet Med Sci. 1998 Mar;60(3):359-60.

49.

Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries.

Masunaga H, Fujise N, Shiota A, Ogawa H, Sato Y, Imai E, Yasuda H, Higashio K.

Eur J Pharmacol. 1998 Jan 26;342(2-3):267-79.

PMID:
9548396
50.

Characterization of structural domains of human osteoclastogenesis inhibitory factor.

Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K.

J Biol Chem. 1998 Feb 27;273(9):5117-23.

Supplemental Content

Loading ...
Support Center